2020 Virtual Student-Centered Workshop on Innovative Solutions to Business Challenges Leading to Paid Internships
Saturday, April 4, 2020
The Italian Research Institute of Georgetown College would like to invite all Georgetown students to apply for participation in an exciting One-Day Student-Centered Workshop: Innovative Solutions to Business Challenges. The Workshop has served as a bridge between business and academia and offers students a great opportunity to intellectually engage in finding solutions to real challenges confronting the business world today. This unique event features leaders from well-known and established Italian companies who will challenge students to come up with innovative solutions to these issues. The workshop encourages students to engage in collaborative research that will lead to paid internship opportunities with the firms.
This year, top executives from the two participating Italian companies, Eni S.p.A. and Kedrion Biopharma S.p.A. will present the challenges to students. The participating students, divided into small groups, will work together and present a solution to the challenge. At the end of the day, the respective business leaders, faculty, and the Institute director will select the winning teams who will be offered paid internship opportunities and other perks.
Italian Multinational Oil & Gas Company
Eni is a global energy major, headquartered in Rome. With €76 billion in revenue, it is Italy’s largest company. It employs 33,000 people in 67 countries across 5 continents. Amongst key presence areas are Europe, MENA, and Sub-Saharan Africa. Eni is a recognized world leader in the Exploration and Production of gas and oil and has a significant presence in downstream energy markets (lubricants, products, retail sales of gas & power), and chemicals. Furthermore, it has expanded its investments to renewable power generation and circular economy applications.
In the US, Eni is presently active in Texas and Alaska in the Oil & Gas business; it has launched an ambitious plan to develop renewable energy projects; it has opened its Corporate Venture Capital initiative. It has offices in Houston, Boston, New York, and Washington DC.
In September 2019, Eni’s Board of Directors approved the company’s new Mission, driven by sustainability and incorporating 8 SDGs into the company’s strategy. And, as a member of the Oil & Gas Climate Initiative, Eni expresses its commitment to leading the reduction of the energy value chain carbon footprint. Beyond policy, Eni is investing in digitalization, energy efficiency, alternative power generation systems (renewable and nuclear fusion), etc. in a coordinated effort to decarbonize the energy system and build a sustainable and innovative energy business.
This is the fifth year Eni has participated in the Georgetown workshop. On a rotating basis, students from the chosen team are offered paid internships at Eni’s Washington DC Office, which ensures Eni relations with US Authorities and policymakers, stakeholders, and opinion makers in the energy and climate sector. Some of the past participants have been offered positions in the company.
Marco Margheri, Senior Vice President of Eni US Representative Office in Washington DC will present a challenge related to advocating the company’s view on the energy transition and supporting the broadening of its interests to new business domains.
Sr. Vice President
Eni US Representative Office, Washington DC
Marco Margheri joined Eni in Oct. 2019 in the International Affairs Department as the SVP for the ENI US Representative Office in Washington DC. His focus will be on relations with US Energy and Climate policymakers and stakeholders, as well as on US Energy and Climate domestic and global policies. He also serves as the Chair for Italy of the WEC – World Energy Council (www.wec-italia.org), is a Member of the Executive Committee of IAI – Istituto Affari Internazionali (www.iai.it), a Council member of the ECFR – European Council on Foreign Relations (www.ecfr.eu). Marco is a visiting professor on EU Energy Policy at LUISS University in Rome.
Marco is enrolled in the Italian Journalists’ Register and is an honorary member of the Milano per la Scala Foundation in Milan. He has been appointed a Chevalier in the Ordre National du Mérite of the French Republic. Prior to joining Eni, Marco Margheri has been Edison’s Executive Vice-President for Sustainability, Institutions & Regulation, and was responsible for Sustainability policies and Corporate Social Responsibility initiatives, as well as for Edison’s advocacy toward Italian, European, and International Institutions and Regulatory Boards, stakeholders and opinion leaders. Marco has previously held positions with General Electric Oil & Gas and with Burson-Marsteller Cohn & Wolfe.
Advocating the Energy Transition
Energy and climate developments are amongst the most important pillars on which the future of our society rests. In the past, it has been technologies and markets alone that have dictated the direction of energy systems. Today, the urge of scaling up the fight against climate change has become a key factor in shaping policies, investment behaviors, and corporate strategies.
Eni has diversified its energy mix to focus on low-emitting natural gas and has launched new business initiatives focusing on renewables, circular economy platforms, and new digital endeavors, while also continuing to meet the global economy’s growing demand for oil in an ever-more sustainable fashion (i.a. via committing to net zero carbon emissions for its upstream business within 2030).
As part of Eni’s work in Washington D.C., Eni’s Representative Office interacts with U.S. law- and policy-makers and stakeholders, in order to communicate the company’s strategy and advocate its historical and new business interests. This requires an advocacy strategy, capable of reaching out to old and new stakeholders and managing potential trade-offs.
Analyze the challenge of adapting corporate advocacy in a changing business and policy environment. Define the key objectives and potential obstacles, analyze Washington D.C.’s policy-making arena for the Oil & Gas and new energy sectors, and identify mutually reinforcing and potentially diverging challenges and interactions. Then, devise an advocacy strategy and plan.
Team 1: Creating Value through the Energy Transition
Team 2: Eni Corporate Advocacy Strategy [Winning Team]
Team 3: Future Opportunity in Natural Gas [References]
Team 4: Empowering Energy Innovation
Team 5: Eni
Team 6: Building a Better World with Renewable Energy
Talal Mohammed Abdul Nasser
Kedrion Biopharma S.p.A.
Italian Biopharmaceutical Company
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating patients suffering from Hemophilia, Primary Immunodeficiencies, and other serious illnesses.
Kedrion puts people at its heart, placing a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves. Kedrion acts as a bridge between donors and the people who need treatments and works on a global scale to expand the patients’ access to available treatments.
Headquartered in Italy, Kedrion Biopharma has a market presence in 100 countries. In the field of plasma derivatives, it is the world’s 5th most important player and Italy’s 1st. The company employs more than 2,500 people, over 1100 of whom are in Italy: over 37% of staff is under the age of 35 and women account for 50% of the workforce.
In Italy, Kedrion is a partner of the National Health System, which it concretely supports in the pursuit of self-sufficiency in the supply of plasma-derived products. At the same time, the company offers its expertise and its efforts to communities and health systems all over the world to achieve the same goal, in the attempt to help improve the quality of life of people with rare diseases.
The company manages the entire plasma transformation cycle (supply, production, and distribution), on a vertical integration business model. Our production plants are in Italy (Bologna and Castelvecchio Pascoli – which is nearing completion – near Lucca, and Sant’Antimo, near Naples), Hungary (in Gödöllő, near Budapest), and the United States (in Melville, New York). Kedrion owns fully-operational plasma collection centers in the United States and Europe. In particular, a collection center in Buffalo, State of New York, specializes in plasma with a high Anti-D antibody content, used to manufacture an Anti-D Immunoglobulin-based medicinal product for the prevention of Haemolytic Disease of the Fetus and the Newborn (HDFN). Paolo Marcucci, President and CEO of Kedrion Biopharma S.p.A. will be presenting the challenge.
President and CEO of Kedrion Biopharma S.p.A.
Paolo Marcucci is President and CEO of Kedrion Biopharma S.p.A. a biopharmaceutical company specializing in the development, production, and distribution of plasma-derived therapies for serious, often rare conditions such as hemophilia and auto-immune disease.
Born in Barga (Lucca, Italy), Mr. Marcucci studied Business and Economics at the University of Pisa (Italy) and holds a Masters degree in Business Administration from the Edhec Business School of Lille and Nice (France).
Under his leadership, Kedrion has grown from its Italian roots into a global entity with operations and subsidiaries in Europe, Latin America, Asia, and the US. Its products are now sold in more than 100 countries. He has served on the Plasma and Protein Therapeutics Association (PPTA) Global Board of Directors since 2009, serving as Chair from 2013 to 2015. Mr. Marcucci has extensive experience in the telecommunications sector as well, having served as CEO of the London-based, pan-European satellite channel from 1998 to 1993.
Plasma Protein therapies treat well-defined medical conditions, replacing missing or deficient proteins found in plasma, allowing their recipients to lead healthier and more productive lives. The patient populations that rely upon plasma protein therapies generally require regular infusions or injections for their entire lives.
The starting material for all the plasma-derivatives medical products is human plasma, collected from remunerated or non-remunerated donors all over the world. Unfortunately, the plasma collected every year is not enough to guarantee access to care for all the patients in need, and plasma-derivative companies such as Kedrion have to carry out choices in allocating the available product throughout the different countries.
In countries like the US, Germany, Austria, Hungary, and Czechia, the blood and plasma system is capable of collecting more plasma than national needs, hence exporting plasma to other countries’ patients. In these countries, plasma collection envisages remuneration/reimbursement for plasma donors. Nonetheless, for cultural and historical reasons it is not foreseeable nor likely whether other countries will choose to give remuneration to their plasma donors.
The students’ groups will work on possible plans to achieve sustainable global plasma collection growth, providing different suggestions for countries with donors’ remuneration and countries based on non-paid plasma donors.
- Kedrion Corporate Presentation (password protected)
- Plasma and Kedrion plasma collection in the USA
- Kedrion Workshop Challenge
Team 1: Keep Life Flowing City by City
Team 2: Marketing Initiatives [Winning Team]
Team 3: Plasma is the Way, Give it Away, Costs Nothing! Means Everything
Sonia Paz Canton
Team 4: Marketing Strategy Proposal